Disease Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Data and Discovery (GRNDaD) Registry

Novartis1 site in 1 country1,665 target enrollmentOctober 6, 2021

ConditionsSickle Cell Disease

Overview

Phase: N/A
Intervention: Not specified
Conditions: Sickle Cell Disease
Sponsor: Novartis
Enrollment: 1665
Locations: 1
Primary Endpoint: Number of Patients in the Globin Research Network for Data and Discovery (GRNDaD) Registry who Received a Disease Modifying Therapy (DMT)
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This was a retrospective observational cohort study. This study was a secondary analysis of individuals with sickle cell disease (SCD) enrolled in the GRNDaD registry.

Registry

clinicaltrials.gov

Start Date

October 6, 2021

End Date

December 1, 2023

Last Updated

last year

Study Type

Observational

Sex

All

Investigators

Sponsor

Novartis

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

Number of Patients in the Globin Research Network for Data and Discovery (GRNDaD) Registry who Received a Disease Modifying Therapy (DMT)

Time Frame: Up to 2 years

DMTs included: hydroxyurea, voxelotor, crizanlizumab, l-glutamine, and chronic red cell transfusion.

Secondary Outcomes

Number of Patients in the Globin Research Network for Data and Discovery (GRNDaD) Registry Using Hydroxyurea Categorized by Gender(Up to 2 years)
Number of Patients in the GRNDaD Registry Using Hydroxyurea Categorized by Genotype(Up to 2 years)
Number of Patients in the GRNDaD Registry Using Hydroxyurea Categorized by Age(Up to 2 years)
Number of Patients in the GRNDaD Registry Using Voxelotor Categorized by Gender(Up to 2 years)
Number of Patients in the GRNDaD Registry Using Voxelotor Categorized by Genotype(Up to 2 years)
Number of Patients in the GRNDaD Registry Using Voxelotor Categorized by Age(Up to 2 years)
Number of Patients in the GRNDaD Registry Using Crizanlizumab Categorized by Gender(Up to 2 years)
Number of Patients in the GRNDaD Registry Using Crizanlizumab Categorized by Genotype(Up to 2 years)
Number of Patients in the GRNDaD Registry Using Crizanlizumab Categorized by Age(Up to 2 years)
Number of Patients in the GRNDaD Registry Using L-glutamine Categorized by Gender(Up to 2 years)
Number of Patients in the GRNDaD Registry Using L-glutamine Categorized by Genotype(Up to 2 years)
Number of Patients in the GRNDaD Registry Using L-glutamine Categorized by Age(Up to 2 years)
Number of Patients in the GRNDaD Registry Using Chronic Transfusion Categorized by Gender(Up to 2 years)
Number of Patients in the GRNDaD Registry Using Chronic Transfusion Categorized by Genotype(Up to 2 years)
Number of Patients in the GRNDaD Registry Using Chronic Transfusion Categorized by Age(Up to 2 years)
Number of Hospital Admissions Categorized by Age(Up to 2 years)
Mean Number of Hospital Admissions(Up to 2 years)
Number of Emergency Department Visits Categorized by Age(Up to 2 years)
Mean Number of Emergency Department Visits(Up to 2 years)